Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
24,514
Total Claims
$2.9M
Drug Cost
752
Beneficiaries
$3,922
Cost/Patient
Risk Score Breakdown 17/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+178%
Cost per patient vs peers
$3,922 vs $1,411 avg
+28%
Brand preference vs peers
13.6% vs 10.6% avg
Brand vs Generic
Brand: 3,294 claims · $2.4M
Generic: 20,930 claims · $502K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Icosapent Ethyl | 731 | $410K |
| Tenofovir Alafenamide | 164 | $274K |
| Dapagliflozin Propanediol | 277 | $261K |
| Dulaglutide | 125 | $154K |
| Empagliflozin/Metformin Hcl | 181 | $146K |
| Denosumab | 75 | $130K |
| Empagliflozin | 125 | $124K |
| Sitagliptin Phosphate | 141 | $117K |
| Rivaroxaban | 106 | $102K |
| Linaclotide | 103 | $85K |
| Lipase/Protease/Amylase | 44 | $76K |
| Dapaglifloz Propaned/Metformin | 70 | $72K |
| Budesonide/Formoterol Fumarate | 113 | $62K |
| Budesonide/Glycopyr/Formoterol | 49 | $41K |
| Sitagliptin Phos/Metformin Hcl | 47 | $40K |
Prescribing Profile
Patient Profile
73
Avg Age
52%
Female
0.97
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data